关于召开2024年年度股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 证券代码：688356 证券简称：键凯科技 公告编号：2025-011 北京键凯科技股份有限公司 （一） 股东大会类型和届次 2024年年度股东大会 （四） 现场会议召开的日期、时间和地点 召开日期时间：2025 年 6 月 10 日 14 点 00 分 召开地点：北京市海淀区西小口路 66 号中关村东升科技园北领地 C6 座凯 莱酒店 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 6 月 10 日 股东大会召开日期：2025年6月10日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 至2025 年 6 月 10 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为 ...

证券代码：688356 证券简称：键凯科技 公告编号：2025-010 北京键凯科技股份有限公司 第三届监事会第十一次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 北京键凯科技股份有限公司（以下简称"公司"）第三届监事会第十一次会议通知 已于 2025 年 4 月 18 日通过通讯方式送达。会议于 2025 年 4 月 28 日以现场及通讯表决 方式在公司会议室召开。本次会议应出席监事 3 名，实际出席监事 3 名。会议由监事会 主席王云秀女士主持。本次会议的召开符合《中华人民共和国公司法》等法律、法规、 规范性文件和《公司章程》的有关规定，会议合法、有效。 二、监事会会议审议情况 经与会监事认真审议，一致通过以下议案： （一）审议并通过《关于<2024 年度监事会工作报告>的议案》 监事会认为公司 2024 年度监事会工作报告是根据相关法律、法规及规范性文件的要 求编制的，真实地反映了监事会 2024 年度的工作情况。本年度公司监事会召开了 5 次 会议，对公司重大决策和决议的形成 ...

证券代码：688356 证券简称：键凯科技 公告编号：2025-009 北京键凯科技股份有限公司 第三届董事会第十二次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 北京键凯科技股份有限公司（以下简称"公司"）第三届董事会第十二次会议通知已 于 2025 年 4 月 18 日通过书面通知的形式送达。会议于 2025 年 4 月 28 日以现场及通讯 表决方式在公司会议室召开。本次会议应出席董事 9 名，实际出席董事 9 名。会议由董 事长赵宣先生主持。本次会议的召开符合《中华人民共和国公司法》等法律、法规、规 范性文件和《公司章程》的有关规定，会议合法、有效。 二、董事会会议审议情况 经与会董事认真审议，本次会议审议通过了如下议案： （一）审议并通过《关于<2024 年度董事会工作报告>的议案》 表决结果：9 票赞成，0 票反对，0 票弃权。 本议案尚需提交公司 2024 年年度股东大会审议。 （二）审议并通过《关于<2024 年度董事会审计委员会履职报告>的议案》 表决结果：9 票赞 ...

重要内容提示： 每股分配比例：每股派发现金红利 0.15 元（含税），不进行公积金转 增股本，不送红股。 本次利润分配以实施权益分派股权登记日登记的总股本扣除存放于股 票回购专用证券账户的股数为基数，具体日期将在权益分派实施公告中明确。在 实施权益分派的股权登记日前公司总股本发生变动的，拟维持分配总额不变，相 应调整每股分配比例，并将另行公告具体调整情况。 公司不会触及《上海证券交易所科创板股票上市规则（2024 年 4 月修 订）》（以下简称《科创板股票上市规则》）第 12.9.1 条第一款第（八）项规 定的可能被实施其他风险警示的情形。 一、利润分配方案内容 （一）利润分配方案的具体内容 证券代码：688356 证券简称：键凯科技 公告编号：2025-013 北京键凯科技股份有限公司 2024 年年度利润分配方案公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 权益分派股权登记日登记的总股本扣除存放于股票回购专用证券账户的股数为 基数分配利润。本次利润分配方案如下： 上市公司拟向全体股东每 10 股派发现金红利 1 ...

Revenue Performance - The company reported a revenue of CNY 69,104,053.22 for the first quarter of 2025, representing a 6.66% increase compared to CNY 64,788,995.56 in the same period last year[4]. - Total revenue for Q1 2025 reached ¥69,104,053.22, an increase of 6.9% compared to ¥64,788,995.56 in Q1 2024[12]. - The company achieved product sales revenue of CNY 67,351,300, a 5.91% increase year-on-year, with domestic sales declining by 68.20% to CNY 7,704,600, while international sales surged by 51.52% to CNY 59,646,700[9]. - Revenue from technical services increased by 74.66% to CNY 1,570,200, with both domestic and international technical service revenues showing growth[9]. Profitability - Net profit attributable to shareholders decreased by 17.79% to CNY 11,880,461.89 from CNY 14,452,078.78 year-on-year[4]. - Net profit for Q1 2025 was ¥11,880,461.89, down 17.5% from ¥14,452,078.78 in Q1 2024[13]. - The company reported a basic earnings per share of ¥0.20 for Q1 2025, down from ¥0.24 in Q1 2024[13]. Operating Activities - The net cash flow from operating activities was negative at CNY -11,064,447.38, a significant decline of 126.28% compared to CNY 42,100,504.42 in the previous year[4]. - Cash flow from operating activities in Q1 2025 was ¥36,285,255.93, significantly lower than ¥108,269,854.28 in Q1 2024, a decline of 66.5%[15]. - Cash outflows related to operating activities totaled $47.35 million, a decrease from $66.17 million, indicating improved cost management[16]. Research and Development - Research and development (R&D) expenses totaled CNY 19,258,551.25, an increase of 19.96% from CNY 16,053,711.87, with R&D expenses accounting for 27.87% of revenue, up from 24.78%[5]. - The company is progressing well with its R&D projects, with CNY 10,807,800 in expense-based R&D and CNY 8,450,700 in capitalized R&D related to the JK1201I project[9]. - Research and development expenses decreased to ¥10,807,829.30 in Q1 2025 from ¥16,053,711.87 in Q1 2024, a reduction of 32.5%[12]. Assets and Liabilities - The company reported a total asset value of CNY 1,374,398,798.49, a slight increase of 0.52% from CNY 1,367,260,388.85 at the end of the previous year[5]. - Total assets as of March 31, 2025, were ¥1,374,398,798.49, a slight increase from ¥1,367,260,388.85 at the end of 2024[11]. - Total liabilities decreased to ¥95,845,000.27 as of March 31, 2025, from ¥100,509,398.52 at the end of 2024, a reduction of 4.6%[11]. Cash Flow and Investments - The net cash flow from operating activities was -$11.06 million, a significant decrease compared to $42.10 million in the previous period, indicating a decline in operational performance[16]. - Total cash inflow from investment activities was $213.85 million, down from $292.21 million, reflecting reduced investment returns[16]. - The net cash flow from investment activities was -$22.47 million, an improvement from -$28.42 million, suggesting better management of investment outflows[16]. - Cash flow from financing activities resulted in a net outflow of -$5.91 million, compared to -$8.63 million previously, indicating a reduction in financing costs[16]. - The total cash and cash equivalents at the end of the period decreased to $102.81 million from $116.26 million, showing a decline in liquidity[16]. Accounts Receivable and Cash Management - Accounts receivable increased to ¥80,605,667.25 as of March 31, 2025, compared to ¥46,125,092.31 at the end of 2024, reflecting a rise of 74.6%[10]. - Cash and cash equivalents decreased to ¥102,812,986.01 as of March 31, 2025, from ¥146,810,151.00 at the end of 2024, a decline of 30%[10]. - The company received $208.11 million from investment recoveries, down from $290.31 million, highlighting a decrease in cash inflows from divestitures[16]. Future Outlook - Direct exports to the United States accounted for 17.36% of total revenue, with expectations of a shift towards non-U.S. customers in 2025[9]. - The company plans to implement new accounting standards starting in 2025, which may affect future financial reporting[16].

Dividend Distribution - The company plans to distribute a cash dividend of 1.50 RMB per 10 shares, totaling 9,075,417.90 RMB (including tax) based on 60,502,786 shares, which represents 30.42% of the net profit attributable to shareholders for the year[7][8]. - The total cash dividend and share repurchase amount to 19,575,755.20 RMB, accounting for 65.61% of the net profit attributable to shareholders for the year[8]. - The total distributable profit available to shareholders as of December 31, 2024, is RMB 68,059,432.92[192]. - The cumulative cash dividend over the last three accounting years amounts to RMB 99,875,473.26, with an average net profit of RMB 110,805,108.36, resulting in a cash dividend ratio of 90.14%[199]. - The company’s board has approved the profit distribution plan, which is subject to shareholder approval at the upcoming general meeting[193]. - The company has maintained compliance with its dividend policy, ensuring transparency and protection of minority shareholders' rights[194]. - The total number of shares eligible for dividend distribution is 60,502,786 after excluding repurchased shares[192]. - The company has not proposed any stock bonus or capital reserve increase in the current profit distribution plan[196]. Financial Performance - In 2024, the company's operating revenue decreased by 22.26% to ¥227,096,825.17 compared to ¥292,118,400.90 in 2023[24]. - The net profit attributable to shareholders fell by 74.22% to ¥29,837,797.00 from ¥115,744,579.80 in the previous year[24]. - The basic earnings per share dropped by 74.48% to ¥0.49, down from ¥1.92 in 2023[25]. - The company's total revenue for the reporting period was 227.10 million RMB, a decrease of 22.26% year-on-year[85]. - The net profit attributable to the parent company was 29.84 million RMB, down 74.22% year-on-year[85]. - The revenue from technical service fees was 17.49 million RMB, accounting for 7.70% of the main business revenue[79]. - The gross profit margin for the main business was 69.21% during the reporting period[80]. - The comprehensive gross profit margin is 69.21%, down 12.04 percentage points year-on-year[90]. - Domestic revenue decreased by 43.62% to 84.73 million RMB, while international revenue increased slightly by 0.37% to 142.37 million RMB[95]. Research and Development - The company's R&D expenditure accounted for 35.21% of operating revenue, an increase of 15.42 percentage points from the previous year[25]. - R&D expenses for 2024 reached CNY 7,994.97 million, an increase of 38.28% year-on-year, representing 35.21% of total sales revenue[38]. - The company has developed several PEG-modified drugs and Class III medical devices, including PEG-Irinotecan for small cell lung cancer, which is currently in Phase III clinical trials[44]. - The company has submitted a registration application for the PEG-crosslinked sodium hyaluronate project (JK-2122H), which has been officially accepted by the National Medical Products Administration[44]. - The company has achieved significant breakthroughs in the domestic production of key lipid materials for mRNA delivery systems, optimizing production processes for 5 key excipients[56]. - The company completed the optimization and improvement of 14 derivative products, developed 84 new structural derivatives, and created 150 analytical methods during the reporting period[69]. - The company applied for 27 new invention patents and was granted 4, bringing the total number of granted invention patents to 108, with 102 still pending[71]. - The company is conducting clinical trials for PEG-irinotecan for small cell lung cancer, with the first patient enrollment expected to be completed by September 30, 2024[65]. Operational Risks and Governance - The company has faced various operational risks, which are detailed in the management discussion and analysis section of the report[4]. - The company has received a standard unqualified audit report from Deloitte Huayong[6]. - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[11]. - The company has not violated decision-making procedures for external guarantees[11]. - The company has confirmed that all board members attended the board meeting[5]. - The company has not disclosed any special arrangements for corporate governance[9]. - The company emphasizes that forward-looking statements regarding future plans and strategies do not constitute substantive commitments to investors[10]. - The company has established a comprehensive governance system, including rules for shareholder meetings, board meetings, and supervisory meetings, to ensure standardized operations[158]. - The company disclosed significant information accurately and timely, maintaining transparency and protecting the interests of minority investors[160]. - There were no significant discrepancies between the company's governance practices and the regulations set by the China Securities Regulatory Commission[160]. Market and Competitive Position - The company is positioned as a leading domestic player in the industrial production of high-purity and low-dispersity medical-grade PEG, filling a long-standing gap in the domestic market for high-quality PEG[41]. - The company is positioned as a major emerging player in the global market for medical-grade PEG and its derivatives[41]. - The company is actively pursuing new applications for high-purity PEG materials in various drug formulations, indicating a commitment to innovation[148]. - The company aims to expand its market presence by developing new applications for PEG derivatives in various downstream industries, targeting rapid growth in the medical and healthcare sectors[152]. - The company is focusing on the development of LNPs delivery technology, which is gaining traction due to the widespread use of mRNA vaccines[148]. - The company is in a performance transition period in 2024, with expectations of growth in overseas pharmaceutical client orders to offset domestic market declines[73]. - The company is actively monitoring international trade policies and maintaining close communication with clients to ensure stable business development amid tariff impacts[73]. Human Resources and Management - The company employed a total of 284 staff members, with 47 in the parent company and 237 in major subsidiaries, including 124 technical personnel[188]. - The company has a competitive compensation policy, providing salaries, bonuses, and various benefits to attract local talent, while managing human resources budgets according to strategic development plans[189]. - The company has implemented an annual training plan to enhance employee skills and support strategic goals, increasing the training budget and encouraging self-learning[190]. - The number of R&D personnel decreased to 80 from 83, while the proportion of R&D personnel in the total workforce increased to 28.17% from 27.85%[68]. - Total compensation for R&D personnel was 2,220.06 million, down from 2,375.44 million, with average compensation decreasing to 27.75 million from 28.62 million[68]. Strategic Investments and Future Plans - The company has made a strategic investment of RMB 21 million in Shanghai Yisi Miao Medical Equipment Co., Ltd., achieving a 100% ownership stake[143]. - The company plans to conduct foreign exchange hedging business as part of its strategy[178]. - The company will use idle funds for wealth management in 2024[178]. - The company aims to optimize operations and governance while actively returning value to investors through its 2024 quality improvement and efficiency enhancement action plan[185]. - The company plans to increase R&D investment to enhance core competitiveness and solidify its technological moat in the PEG materials sector[150]. - The company will focus on developing proprietary products and accelerating the development of self-owned intellectual property products in the PEG derivatives market[152].

关于北京键凯科技股份有限公司 非经营性资金占用及其他关联资金往来情况 汇总表的专项审计报告 目 录 1、 专项审计报告 2、 附表 委托单位：北京键凯科技股份有限公司 审计单位：德勤华永会计师事务所(特殊普通合伙) 联系电话：+86 21 6141 8888 Deloitte. 计师事务所(特殊普通合伙) 北京键凯科技股份有限公司 控股股东、实际控制人及其他关联方资金占用情况的专项说明 德师报(函)字(25)第 Q00659 号 北京键凯科技股份有限公司董事会: 我们接受委托,依据中国注册会计师审计准则审计了北京键凯科技股份有限公司(以下简称"贵公 司")2024年12月31日合并及公司资产负债表,2024年度合并及公司利润表、合并及公司现金流量表、 合并及公司股东权益变动表以及相关财务报表附注(以下合称"财务报表"),并于 2025年 4 月 29 日签发 了德师报(审)字(25)第 P00383 号无保留意见的审计报告。 根据中国证券监督管理委员会联合公安部、国务院国有资产监督管理委员会及中国银行保险监督 管理委员会公布的《上市公司监管指引第 8号 -- 上市公司资金往来、对外担保的监管要求》的要求, 贵 ...

对募集资金存放与实际使用情况专项报告 2024 年 12 月 31 日止年度 北京键凯科技股份有限公司 the De oitte. 华永会计师事务所(特殊普通合伙) 对募集资金存放与实际使用情况专项报告的审核报告 德师报(核)字(25)第 E01017 号 (第1页,共2页) 北京键凯科技股份有限公司董事会: 我们审核了后附的北京键凯科技股份有限公司(以下简称"键凯科技")截至 2024年 12月 31 日止募 集资金存放与实际使用情况的专项报告(以下简称"募集资金存放与实际使用情况报告")。 一、董事会对募集资金存放与实际使用情况报告的责任 按照中国证券监督管理委员会《上市公司监管指引第 2 号 -- 上市公司募集资金管理和使用的监 管要求》及《上海证券交易所科创板上市公司自律监管指引第 1 号 -- 规范运作》的规定编制募集资 金存放与实际使用情况报告,并保证募集资金存放与实际使用情况报告的内容真实、准确、完整,且 不存在虚假记载、误导性陈述或重大遗漏是键凯科技董事会的责任。 二、注册会计师的责任 我们的责任是在实施审核工作的基础上对募集资金存放与实际使用情况报告发表意见。我们按照 《中国注册会计师其他鉴 ...

中信证券股份有限公司关于 北京键凯科技股份有限公司 2024 年度募集资金存放与使用情况的专项核查意见 中信证券股份有限公司（以下简称"中信证券"或"保荐机构"）作为北京键凯 科技股份有限公司（以下简称"键凯科技"或"公司"）首次公开发行的保荐机构， 根据《证券发行上市保荐业务管理办法》《上海证券交易所科创板上市公司自律 监管指引第 1 号——规范运作》《上市公司监管指引第 2 号——上市公司募集资 金管理和使用的监管要求》《上海证券交易所科创板股票上市规则》《科创板上 市公司持续监管办法（试行）》等有关规定，对键凯科技 2024 年度募集资金的 存放和使用情况进行了专项核查，核查情况如下： 一、募集资金基本情况 （一）实际募集资金金额、资金到位时间 根据中国证券监督管理委员会于 2020 年 7 月 28 日签发的证监许可 [2020]1579 号文《关于同意北京键凯科技股份有限公司首次公开发行股票注册的 批复》，键凯科技于 2020 年 8 月向社会公众发行人民币普通股 15,000,000 股， 每股发行价格为人民币 41.18 元，股款以人民币缴足，计人民币 617,700,000.00 元，扣除承销 ...

北京键凯科技股份有限公司全体股东: 北京键凯科技股份有限公司 内部控制审计报告 2024 年 12 月 31 日止年度 Deloitte. 永会计师事务所(特殊普通合伙) 上一年龄// / = 北京键凯科技股份有限公司 内部控制审计报告 德师报(审)字(25)第 S00405 号 (第1页,共2页) 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求,我们审计了北 京键凯科技股份有限公司(以下简称"贵公司")2024年12月 31 日的财务报告内部控制的有效 性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业内部控制评价指 引》的规定,建立健全和有效实施内部控制,并评价其有效性是贵公司董事会的责任。 二、注册会计师的责任 我们的责任是在实施审计工作的基础上,对财务报告内部控制的有效性发表审计意见, 并对注意到的非财务报告内部控制的重大缺陷进行披露。 三、内部控制的固有局限性 内部控制具有固有局限性,存在不能防止和发现错报的可能性。此外,由于情况的变化 可能导致内部控制变得不恰当,或对控制政策和程序遵循的程度降低,根据内部控制审计结 果推测未来内部控制的有 ...